The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy
Authors:
- 30 May 2019
- journal article
- review article
- Published by SAGE Publications in Obstetric Medicine
- Vol. 13 (1) , 5-13
Abstract
In an age where autoimmune rheumatic diseases are successfully managed with biologics, their discontinuation in pregnancy is inadvisable without careful forethought; maternal disease activity is associated with adverse pregnancy outcomes, which has long-term implications for both mother and offspring. We aim to provide clinicians with the necessary tools to facilitate decision-making – when a biologic should be used, when it can be discontinued in pregnancy if appropriate. The pathophysiology of these biologic molecules and their effect on fertility, pregnancy and parturition are discussed. A summary of the 2016 international guidelines (European League Against Rheumatism and British Society in Rheumatology) on biologics in pregnancy has been tabulated; more recent publications are discussed in depth. Data on transplacental-transfer ratios and breastmilk excretion rates are also included. Biologic effects on organogenesis, their implications for the exposed infant in terms of infection risks and vaccination requirements are included, and future directions for research proposed.Keywords
This publication has 87 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal ExposureClinical Gastroenterology and Hepatology, 2013
- Spontaneous abortion during ustekinumab therapyJournal of Dermatological Case Reports, 2012
- Die‐Off Ratio Correlates with IncreasedTNF‐α:IL‐10 Ratio and DecreasedIVFSuccess Rates Correctable withHumiraAmerican Journal of Reproductive Immunology, 2012
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Pregnancy outcomes after maternal exposure to rituximabBlood, 2011
- Neonatal Fc Receptor: From Immunity to TherapeuticsJournal of Clinical Immunology, 2010
- Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeedingRheumatology, 2010
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell DevelopmentJournal of Immunology Research, 2008